**Table S2.** Results of sensitivity analysis for standardized estimates in BCLC stage A

|  |  |  |  |
| --- | --- | --- | --- |
| **Estimand** | **Model 11** | **Model 22** | **Model 33** |
| **Estimate (95% CI)** | **Estimate (95% CI)** | **Estimate (95% CI)** |
| **Risk difference** | 0.03 (0.00-0.06) | 0.04 (0.01-0.07) | 0.01 (-0.01-0.03) |
| **Relative risk** | 1.28 (0.99-1.57) | 1.32 (1.02-1.63) | 1.10 (0.91-1.28) |
| **Odds ratio** | 1.32 (0.98-1.68) | 1.38 (1.01-1.75) | 1.11 (0.90-1.33) |

1 Interaction term between Treatment, BCLC stage, and AFP level and other confounders are included in the model; 2 Interaction term between Treatment, BCLC stage, and Cause of liver cancer and other confounders are included in the model; 3 Interaction term between Treatment and CPC and other confounders are included in the model